

Press Release – Basel, Switzerland, August 26, 2005

Genedata Expressionist® takes lead in mass spectrometry-based biomarker discovery

Genedata AG announces the expansion of its Expressionist software product to integrate mass spectrometry (MS) analysis with its combined omics data analysis platform, the first commercially available analysis solution for this integration. The software will be demonstrated for the first time at the annual HUPO meeting, held next week in Munich, Germany (August 28th-September 1st) and released at this time.

“Our biggest challenge was to accommodate the large raw MS data formats, sometimes tens of gigabytes in size, into our detailed quality assurance workflow”, described Jens Hoefkens, PhD, Project Manager of Expressionist, Genedata AG. The expanded platform supports analysis of gel-free proteomics and metabolomics technologies, including hyphenated MS technologies. The tools are able to load raw spectrographic signals as input.

“We have developed these new tools in close collaboration with our longstanding industrial partners”, explained Dr Daniel Keesman, CEO of Genedata AG. The development included an extensive survey of MS technologies by engineers and physicists at Genedata’s research center in Munich, Germany. The result is a highly automated and standardized MS data processing platform, integrated seamlessly with Expressionist’s existing analysis applications for transcriptomic and gels-based proteomic data. Pharmaceutical companies are combining data from multiple technologies, including MS, in their biomarker discovery efforts. “It is the degree of integration that makes our new MS analysis applications so valuable for biomarker discovery and represents a major step in enhancing the value of Expressionist.”

About Genedata AG

Genedata specializes in computational solutions for life science research, drug discovery, and drug development. The Company combines a comprehensive, scientifically validated computational platform with expert scientific consulting services to provide tailor-made solutions for specific applications and multiple therapeutic areas. Founded in 1997 as a spin-off from Novartis, the Company is privately held and has grown to an interdisciplinary, international team of dedicated experts. Genedata is headquartered in Basel (Switzerland) with subsidiaries and branch offices in Munich (Germany), San Francisco (USA), and Boston (USA). The Company is also represented by Infocom Corporation (Japan), DigiGenomics (Taiwan), and Research Instruments (Singapore, Malaysia).

Contact

Genedata AG
Michael Brueckmann
Marketing Communications
Phone +41 (0)61 697 7701
Fax +41 (0)61 697 7244
Michael.Brueckmann@genedata.com
www.genedata.com

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.